Literature DB >> 26195273

Hemorrhagic effects of oral anticoagulants: a comparative study between vitamin K antagonists (VKA) and direct oral anticoagulants (DOA).

J L Montastruc1, V Rousseau2, L Chebane2, D Abadie2, E Bondon-Guitton2, G Durrieu2, F Montastruc2, H Bagheri2.   

Abstract

Entities:  

Keywords:  Adverse drug reactions; Bleedings; Dabigatran; Direct oral anticoagulants; Pharmacovigilance; Vitamin K antagonists; Warfarin

Mesh：

Substances：

Year:  2015        PMID： 26195273     DOI： 10.1007/s00228-015-1905-0

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  11 in total

1.  Is reporting rate a good predictor of risks associated with drugs?

Authors:  C Pierfitte; B Bégaud; R Lagnaoui; N D Moore
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

2.  Risk of bleeding with dabigatran in atrial fibrillation.

Authors:  Inmaculada Hernandez; Seo Hyon Baik; Antonio Piñera; Yuting Zhang
Journal:  JAMA Intern Med       Date:  2015-01       Impact factor: 21.873

3.  Rates of spontaneous reporting of adverse drug reactions in France.

Authors:  Bernard Bégaud; Karin Martin; Françoise Haramburu; Nicholas Moore
Journal:  JAMA       Date:  2002-10-02       Impact factor: 56.272

4.  Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region).

Authors:  Chiara Biagi; Nicola Montanaro; Elena Buccellato; Giuseppe Roberto; Alberto Vaccheri; Domenico Motola
Journal:  Eur J Clin Pharmacol       Date:  2012-06-17       Impact factor: 2.953

5.  Dabigatran and postmarketing reports of bleeding.

Authors:  Mary Ross Southworth; Marsha E Reichman; Ellis F Unger
Journal:  N Engl J Med       Date:  2013-03-13       Impact factor: 91.245

6.  The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.

Authors:  Francois Montastruc; Agnès Sommet; Emmanuelle Bondon-Guitton; Geneviève Durrieu; Eric Bui; Haleh Bagheri; Maryse Lapeyre-Mestre; Laurent Schmitt; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2011-11-25       Impact factor: 2.953

7.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

Authors:  Christian T Ruff; Robert P Giugliano; Eugene Braunwald; Elaine B Hoffman; Naveen Deenadayalu; Michael D Ezekowitz; A John Camm; Jeffrey I Weitz; Basil S Lewis; Alexander Parkhomenko; Takeshi Yamashita; Elliott M Antman
Journal:  Lancet       Date:  2013-12-04       Impact factor: 79.321

8.  Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Authors:  David J Graham; Marsha E Reichman; Michael Wernecke; Rongmei Zhang; Mary Ross Southworth; Mark Levenson; Ting-Chang Sheu; Katrina Mott; Margie R Goulding; Monika Houstoun; Thomas E MaCurdy; Chris Worrall; Jeffrey A Kelman
Journal:  Circulation       Date:  2014-10-30       Impact factor: 29.690

9.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

10.  Differences between clinical trials and postmarketing use.

Authors:  Karin Martin; Bernard Bégaud; Philippe Latry; Ghada Miremont-Salamé; Annie Fourrier; Nicholas Moore
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335
View more
  1 in total

1.  Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients.

Authors:  Laurent Lafarge; Fouzi Khayi; Anis Bel-Kamel; Nicolas Charhon; Laura Sarfati; Benoit Falquet; Michel Ducher; Laurent Bourguignon
Journal:  Drugs Aging       Date:  2018-06       Impact factor: 3.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.